Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
30
RGLS Quote, Financials, Valuation and Earnings
Last price:
$1.54
Seasonality move
:
7.82%
Day range:
$1.51 - $1.54
52-week range:
$1.08 - $3.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.16x
Volume:
46K
Avg. volume:
281.3K
1-year change:
17.56%
Market cap:
$100.9M
Revenue:
--
EPS (TTM):
-$1.06
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | -$0.17 | -- | -41.03% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
$1.54 | -- | $100.9M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.42 | -- | $22.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.54 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.38 | -- | $4.6M | -- | $0.00 | 0% | 1.49x |
|
PTN
Palatin Technologies
|
$0.99 | -- | $19.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.76 | $100.00 | $4.9M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | 3.126 | -- | -- |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | -$15.2M | -- | -- | -- | -$9.5M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
Regulus Therapeutics vs. Competitors
-
Which has Higher Returns RGLS or IBIO?
iBio has a net margin of -- compared to Regulus Therapeutics's net margin of -4444.57%. Regulus Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.21 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About RGLS or IBIO?
Regulus Therapeutics has a consensus price target of --, signalling upside risk potential of 571%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that Regulus Therapeutics has higher upside potential than iBio, analysts believe Regulus Therapeutics is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics0 0 0 IBIOiBio0 0 0 -
Is RGLS or IBIO More Risky?
Regulus Therapeutics has a beta of 1.612, which suggesting that the stock is 61.188% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock RGLS or IBIO?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or IBIO?
Regulus Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Regulus Therapeutics's net income of -$14.1M is lower than iBio's net income of -$4M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$14.1M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns RGLS or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Regulus Therapeutics's net margin of -49.65%. Regulus Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.21 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About RGLS or NBY?
Regulus Therapeutics has a consensus price target of --, signalling upside risk potential of 571%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Regulus Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is RGLS or NBY More Risky?
Regulus Therapeutics has a beta of 1.612, which suggesting that the stock is 61.188% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock RGLS or NBY?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or NBY?
Regulus Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Regulus Therapeutics's net income of -$14.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$14.1M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns RGLS or OGEN?
Oragenics has a net margin of -- compared to Regulus Therapeutics's net margin of --. Regulus Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.21 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About RGLS or OGEN?
Regulus Therapeutics has a consensus price target of --, signalling upside risk potential of 571%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23709.52%. Given that Oragenics has higher upside potential than Regulus Therapeutics, analysts believe Oragenics is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics0 0 0 OGENOragenics0 0 0 -
Is RGLS or OGEN More Risky?
Regulus Therapeutics has a beta of 1.612, which suggesting that the stock is 61.188% more volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock RGLS or OGEN?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or OGEN?
Regulus Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Regulus Therapeutics's net income of -$14.1M is lower than Oragenics's net income of -$2.5M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 1.49x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$14.1M OGENOragenics1.49x -- -- -$2.5M
-
Which has Higher Returns RGLS or PTN?
Palatin Technologies has a net margin of -- compared to Regulus Therapeutics's net margin of -2357.27%. Regulus Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.21 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About RGLS or PTN?
Regulus Therapeutics has a consensus price target of --, signalling upside risk potential of 571%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Regulus Therapeutics, analysts believe Palatin Technologies is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics0 0 0 PTNPalatin Technologies0 0 0 -
Is RGLS or PTN More Risky?
Regulus Therapeutics has a beta of 1.612, which suggesting that the stock is 61.188% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock RGLS or PTN?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or PTN?
Regulus Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Regulus Therapeutics's net income of -$14.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$14.1M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns RGLS or TOVX?
Theriva Biologics has a net margin of -- compared to Regulus Therapeutics's net margin of --. Regulus Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.21 -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About RGLS or TOVX?
Regulus Therapeutics has a consensus price target of --, signalling upside risk potential of 571%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5042.05%. Given that Theriva Biologics has higher upside potential than Regulus Therapeutics, analysts believe Theriva Biologics is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics0 0 0 TOVXTheriva Biologics1 0 0 -
Is RGLS or TOVX More Risky?
Regulus Therapeutics has a beta of 1.612, which suggesting that the stock is 61.188% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock RGLS or TOVX?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or TOVX?
Regulus Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Regulus Therapeutics's net income of -$14.1M is lower than Theriva Biologics's net income of -$7.7M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$14.1M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
